Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX6PLV)

Drug Name

Sodium valproate Drug Info

Synonyms

Sodium valproate; Sodium 2-propylpentanoate; 1069-66-5; Valproate sodium; Valproic acid sodium salt; Labazene; Eurekene; Orfiril; Valproic acid sodium; Epilim; Valerin; Natrium valproat; Sodium 2-propylvalerate; 2-Propylvaleric acid sodium salt; Pentanoic acid, 2-propyl-, sodium salt; 2-Propylpentanoic acid sodium salt; DEPACON; Sodium dipropylacetate; Dipropylacetate sodium; Sodium bispropylacetate; Valproinsaeure, natrium; Sodium n-dipropylacetate; UNII-5VOM6GYJ0D; Valproic Acid, Sodium Salt; Valproic Acid (sodium salt); Sodium 2

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 16760703
ChEBI ID: CHEBI:9925
CAS Number: CAS 1069-66-5
TTD Drug ID: DMX6PLV

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting GABA transaminase (ABAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-Alanine	DMZDN4W	Dietary shortage	5B5K	Approved	[2]
Pyridoxal Phosphate	DMO2K0J	Malnutrition	5B50-5B71	Approved	[2]
Pyruvic acid	DM7Q41G	Malnutrition	5B50-5B71	Approved	[2]
Vigabatrin	DMYT0OG	Alcohol dependence	6C40.2	Approved	[3]
Divalproex sodium	DM4RK0G	Seizure disorder	8A6Z	Approved	[2]
CPP-115	DMK9NQI	Tourette syndrome	8A05.00	Phase 2	[4]
K-828-AB	DMJLNZQ	Dementia	6D80-6D86	Phase 2	[5]
CPP -15	DMQCHU3	Infantile spasm	8A62.0	Phase 1	[4]
T83193	DMHO29Y	Discovery agent	N.A.	Patented	[6]
4-hydroxybenzaldehyde	DM471P5	Discovery agent	N.A.	Patented	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GABA transaminase (ABAT)	TTT2LD9	GABT_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Influence of a GABA transaminase inhibitor on central nervous system oxygen toxicity. Aviat Space Environ Med. 1978 Jul;49(7):877-9.
2	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
3	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
4	Clinical pipeline report, company report or official report of Catalyst Pharma.
5	Phase II clinical trial of K-828-AB for treating behavioral and psychological symptoms of dementia. Kowa Co. Ltd.
6	Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5.
7	Inactivation of GABA transaminase by 3-chloro-1-(4-hydroxyphenyl)propan-1-one. Bioorg Med Chem Lett. 2009 Feb 1;19(3):731-4.